Lee et al. confirmed a significant increase in RIPK3 and MLKL in ulcerative colitis patient tissues, and treatment with the RIPK3 inhibitor, GSK’872, in peripheral blood mononuclear cells isolated from the patient suppressed the activated inflammatory response [22]. This evidence concerns the gene MLKL and ulcerative colitis.